Evolus to Report Fourth Quarter and Year End 2024 Results on March 4, 2025

Rhea-AI Summary

Evolus (NASDAQ: EOLS), a performance beauty company focused on building an aesthetic portfolio of consumer brands, has scheduled its fourth quarter and year end 2024 financial results announcement for Tuesday, March 4, 2025, after U.S. financial markets close.

The company will host a conference call and live webcast at 4:30 p.m. ET on the same day, featuring management presentations followed by a question-and-answer session. Participants can join via phone by dialing (877) 407-6184 (U.S.) or (201) 389-0877 (international), or through the live webcast on Evolus's Investor Relations webpage.

After the call, a replay will be available by dialing (877) 660-6853 (U.S.) or (201) 612-7415 (international) using conference number 13751816. An archived webcast will also be accessible on the company's website.

NEWPORT BEACH, Calif.--(BUSINESS WIRE)-- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its fourth quarter and year end 2024 financial results on Tuesday, March 4, 2025, after the U.S. financial markets close.

Evolus management will host a conference call and live webcast to discuss these results at 4:30 p.m. ET that same day. A question-and-answer session will follow management’s remarks.

To participate in the conference call, dial (877) 407-6184 (U.S.) or (201) 389-0877 (international) or connect live via webcast on the Investor Relations page of the Evolus website here.

Following the completion of the call, a telephonic replay can be accessed by dialing (877) 660-6853 (U.S.) or (201) 612-7415 (international) and using conference number 13751816. An archived webcast can also be accessed on the Investor Relations page of the Evolus website at www.evolus.com.

About Evolus, Inc.

Evolus (NASDAQ: EOLS) is a global performance beauty company redefining the aesthetic injectable market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global leader in aesthetics anchored by our flagship products: Jeuveau^® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics, and Evolysse^™, a collection of unique injectable hyaluronic acid (HA) gels. Visit us at www.evolus.com, and follow us on LinkedIn, X, Instagram or Facebook.

Jeuveau^® and Nuceiva^®, are registered trademarks and Evolysse^™ is a trademark of Evolus, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250218537551/en/

Investors:

Nareg Sagherian, Vice President, Head of Global Investor Relations and Corporate Communications

Phone: (248) 202-9267

Email: ir@evolus.com

Media:

Email: media@evolus.com

Source: Evolus

FAQ

When will Evolus (EOLS) release its Q4 and full-year 2024 earnings?

Evolus will release its Q4 and full-year 2024 earnings on Tuesday, March 4, 2025, after U.S. financial markets close.

What time is the Evolus (EOLS) Q4 2024 earnings call?

The Evolus Q4 2024 earnings conference call is scheduled for 4:30 p.m. ET on March 4, 2025.

How can investors join the Evolus (EOLS) Q4 2024 earnings call?

Investors can join by dialing (877) 407-6184 (U.S.) or (201) 389-0877 (international), or by accessing the live webcast on Evolus's Investor Relations webpage.

How can investors access the replay of Evolus (EOLS) Q4 2024 earnings call?

Investors can access the replay by dialing (877) 660-6853 (U.S.) or (201) 612-7415 (international) using conference number 13751816, or by viewing the archived webcast on Evolus's website.